{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:11:21Z","timestamp":1792681881274,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Emergence of extensively drug-resistant (XDR) or pan drug-resistant (PDR) <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic> is a major public threat especially for young patients. Treatment options for these bacteria are extremely limited with no safety data existing for neonates and children. Ceftazidime-avibactam has activity against Gram-negative bacteria producing <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic> carbapenemase, but virtually no data exist on its use in neonatal and pediatric patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We present a single-center case series of neonates and children &lt;5 years treated with ceftazidime-avibactam for XDR or PDR <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic> infections until August 2018. Medical records of patients who received ceftazidime-avibactam for at least 2 days (6 doses) were reviewed. Clinical, laboratory and microbiologic data were collected using a prestructured form. Adverse events and clinical\/microbiologic responses and 15- and 30-day outcome were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In our case series, 8 patients (median age 53 days, range from 13 days to 4.5 years) received 9 courses of ceftazidime-avibactam at a dose of 62.5\u2009mg\/kg q8h for suspected or proven XDR\/PDR <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic> infections including bloodstream infections (8 courses), central nervous system infections (2 courses) and urinary tract infection (1 course). All patients were critically ill and received other antibiotics prior and concomitantly with the administration of ceftazidime-avibactam. There was no treatment discontinuation due to adverse events. Clinical and microbiologic responses occurred in all patients, and no patient died by day 30.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Administration of ceftazidime-avibactam appears to be well tolerated and efficacious against in vitro susceptible XDR or PDR <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic> without being associated with significant adverse events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002344","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:13:07Z","timestamp":1558753987000},"page":"812-815","source":"Crossref","is-referenced-by-count":60,"title":["Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children &lt;5 Years of Age"],"prefix":"10.1097","volume":"38","author":[{"given":"Elias","family":"Iosifidis","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, 3rd Department of Pediatrics, Medical Faculty, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisavet","family":"Chorafa","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, 3rd Department of Pediatrics, Medical Faculty, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Agakidou","sequence":"additional","affiliation":[{"name":"1st Department of Neonatology and Neonatal Intensive Care Unit, Medical Faculty, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggeliki","family":"Kontou","sequence":"additional","affiliation":[{"name":"1st Department of Neonatology and Neonatal Intensive Care Unit, Medical Faculty, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asimina","family":"Violaki","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Volakli","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni-Ifigeneia","family":"Christou","sequence":"additional","affiliation":[{"name":"Pharmacy Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Zarras","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hippokration General Hospital, Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Drossou-Agakidou","sequence":"additional","affiliation":[{"name":"1st Department of Neonatology and Neonatal Intensive Care Unit, Medical Faculty, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sdougka","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, 3rd Department of Pediatrics, Medical Faculty, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QCO.0000000000000493","article-title":"Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.","volume":"31","author":"Tumbarello","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17425255.2017.1230200","article-title":"Colistin: still a lifesaver for the 21st century?","volume":"13","author":"Karaiskos","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/cid\/cis543","article-title":"Carbapenem-resistant Enterobacteriaceae: an emerging problem in children.","volume":"55","author":"Logan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1573396314666180308150908","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: novel therapy for multidrug resistant Gram negative infections in children.","volume":"14","author":"Rodriguez","year":"2018","journal-title":"Curr Pediatr Rev"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20230912","first-page":"316","article-title":"Demographic profile and outcome analysis of pediatric intensive care patients.","volume":"15","author":"Volakli","year":"2011","journal-title":"Hippokratia"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00134-017-5021-8","article-title":"Prognostic accuracy of age-adapted SOFA, SIRS, PELOD-2, and qSOFA for in-hospital mortality among children with suspected infection admitted to the intensive care unit.","volume":"44","author":"Schlapbach","year":"2018","journal-title":"Intensive Care Med"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/14767058.2017.1315665","article-title":"Assessment of sickness severity of illness in neonates: review of various neonatal illness scoring systems.","volume":"31","author":"Garg","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in pharmacovigilance.","volume":"10","author":"Edwards","year":"1994","journal-title":"Drug Saf"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jac\/dkx358","article-title":"Ceftazidime\/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report.","volume":"73","author":"Holyk","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/ofid\/ofw172.885","article-title":"Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.","volume":"3","author":"Samuel","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2146\/ajhp170632","article-title":"Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin.","volume":"75","author":"Gofman","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2016.11.005","article-title":"Clinical experience with ceftazidime\/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa.","volume":"49","author":"Xipell","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"e00464","DOI":"10.1128\/AAC.00464-17","article-title":"Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration.","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections.","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/jac\/dkx179","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.","volume":"72","author":"Both","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment.","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"e02101","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates.","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10096-018-3215-9","article-title":"Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 \u03bcg.","volume":"37","author":"Koeth","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201908000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:55:54Z","timestamp":1694559354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201908000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002344","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}